Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML [Phase 3]
Phase 3 study comparing ASTX727 (cedazuridine/decitabine) versus intravenous decitabine in myelodysplastic syndromes, chronic myelomonocytic…
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 [Phase 2]
A Phase 2 trial completed evaluating in vivo azacitidine incorporation in mononuclear cells after Vidaza or CC-486 treatment in patients wit…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Classical Monocyte Kinetics in Chronic Myelomonocytic Leukemia [NA]
A clinical trial investigating classical monocyte kinetics in chronic myelomonocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome [Phase 1, Phase 2]
Phase 1/2 clinical trial of IGF-MTX Conjugate for myelodysplastic syndromes and related hematologic conditions has been terminated, with res…
-
FDA approval · 2024-05-16FDA Approved: AZACITIDINE — Original Application (Sandoz Inc)
FDA approved Sandoz Inc.'s generic azacitidine (AZACITIDINE) as an Original Application under ANDA212580.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome [Phase 1, Phase 2]
This update reports completion of a Phase 1/2 study evaluating the glutaminase inhibitor Telaglenastat (CB-839) in combination with azacitid…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients [Phase 2]
Pilot Phase 2 study evaluating CC-486 (oral azacitidine) plus best supportive care as maintenance after subcutaneous azacitidine in elderly …
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]
A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unre…
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing adding venetoclax to FLAMSA/treosulfan conditioning for allogeneic stem cell transplantation in patient…
-
CLINICAL_TRIALS withdrawal · 2024-04-29Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD [Phase 1, Phase 2]
The trial update indicates that the Phase 1/2 study of high-dose post-transplant cyclophosphamide, bortezomib, and sitagliptin for preventio…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders …
-
FDA approval · 2024-03-29FDA Approved: AZACITIDINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for azacitidine from Accord Healthcare Inc., enabling continued regulatory authorization of the gene…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]
Phase 1/2 trial evaluating quizartinib with azacitidine or cytarabine in relapsed or refractory acute myeloid leukemia and myelodysplastic s…
-
CLINICAL_TRIALS trial_result · 2024-02-15Clinical Trial Update: Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating chemotherapy in patients with myelodysplastic syndromes prior to donor stem cell transplantation has completed with…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS [Phase 1, Phase 2]
Clinical trial update on APG-115 alone or with azacitidine in patients with AML, CMML, or MDS across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML [Phase 3]
Phase 3 continuation study of azacitidine with or without glasdegib in untreated AML, MDS, or CMML; trial completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 clinical trial comparing 5-azacytidine alone versus 5-azacytidine followed by allogeneic stem cell transplantation in elderly patien…
-
CLINICAL_TRIALS trial_result · 2023-10-24Clinical Trial Update: HCT With PTCy in Higher-risk MDS [Phase 2]
Phase 2 clinical trial evaluating haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in higher-risk mye…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion [Phase 2]
This entry details a Phase 2 expansion study of ruxolitinib for chronic myelomonocytic leukemia, with results posted in October 2023.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Methods of T Cell Depletion Trial (MoTD) [Phase 2]
Phase 2 trial update for methods of T cell depletion in various hematologic malignancies is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease [Phase 2]
Phase 2 clinical trial investigating salsalate, venetoclax, and decitabine or azacitidine for acute myeloid leukemia and advanced myelodyspl…
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs [Phase 3]
Phase 3 trial evaluating guadecitabine (SGI-110) vs treatment choice in adults with myelodysplastic syndromes or chronic myelomonocytic leuk…
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial evaluating Clofarabine plus Melphalan as a conditioning regimen before donor stem cell transplantation for patients with myelo…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome [Phase 1]
Phase 1 trial of a conditioning regimen including an iodine-131 labeled monoclonal antibody with fludarabine, cyclophosphamide, total-body i…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…